Literature DB >> 18158123

Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.

Rene J Duquesnoy1, Yehia Awadalla, Jon Lomago, Larry Jelinek, Judy Howe, Dwayne Zern, Betty Hunter, Joan Martell, Alin Girnita, Adriana Zeevi.   

Abstract

This report describes a detailed analysis how donor-specific HLA class II epitope mismatching affects antibody reactivity patterns in 75 solid organ transplant recipients with an in situ allograft and who were considered for retransplantation. Sera were tested for antibodies in a sensitive antigen-binding assay (Luminex) with single class II alleles. Their reactivity was analyzed with HLAMatchmaker, a structural matching algorithm that considers so-called eplets to define epitopes recognized by antibodies. Only 24% of the patients showed donor-specific anti-DRB1 antibodies and there was a significant correlation with a low number of mismatched DRB1 eplets. This low detection rate of anti-DRB1 antibodies may also be due to allograft absorption. In contrast, antibodies to DRB3/4/5 mismatches were more common. Especially, 83% of the DRB4 (DR53) mismatches resulted in detectable antibodies against an eplet uniquely found on DR53 antigens. Donor-specific DQB mismatches led to detectable anti-DQB antibodies with a frequency of 87%. Their specificity correlated with eplets uniquely found on DQ1-4. The incidence of antibodies induced by 2-digit DQA mismatches was 64% and several eplets appeared to play a dominant role. These findings suggest that both alpha and beta chains of HLA-DQ heterodimers have immunogenic epitopes that can elicit specific antibodies. About one-third of the sera had anti-DP antibodies; they reacted primarily with two DPB eplets and an allelic pair of DPA eplets. These data demonstrate that HLA class II reactive sera display distinct specificity patterns associated with structurally defined epitopes on different HLA-D alleles.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18158123      PMCID: PMC2724998          DOI: 10.1016/j.trim.2007.10.001

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  52 in total

1.  Kidney graft failure and presensitization against HLA class I and class II antigens.

Authors:  Caner Süsal; Gerhard Opelz
Journal:  Transplantation       Date:  2002-04-27       Impact factor: 4.939

2.  Common and well-documented HLA alleles: report of the Ad-Hoc committee of the american society for histocompatiblity and immunogenetics.

Authors:  Pedro Cano; William Klitz; Steven J Mack; Martin Maiers; Steven G E Marsh; Harriet Noreen; Elaine F Reed; David Senitzer; Michelle Setterholm; Anajane Smith; Marcelo Fernández-Viña
Journal:  Hum Immunol       Date:  2007-02-15       Impact factor: 2.850

3.  Susceptibility of lung transplants to preformed donor-specific HLA antibodies as detected by flow cytometry.

Authors:  J C Scornik; D S Zander; M A Baz; W H Donnelly; E D Staples
Journal:  Transplantation       Date:  1999-11-27       Impact factor: 4.939

4.  All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies.

Authors:  Po-Chang Lee; Paul I Terasaki; Steven K Takemoto; Po-Huang Lee; Chung-Jye Hung; Yi-Lin Chen; Alen Tsai; Huan-Yao Lei
Journal:  Transplantation       Date:  2002-10-27       Impact factor: 4.939

5.  Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression.

Authors:  Kimberly A Muczynski; David M Ekle; David M Coder; Susan K Anderson
Journal:  J Am Soc Nephrol       Date:  2003-05       Impact factor: 10.121

6.  B-Cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients.

Authors:  Richard J Mahoney; Sarah Taranto; Erick Edwards
Journal:  Hum Immunol       Date:  2002-04       Impact factor: 2.850

7.  Human leukocyte antigens DR and AB and kidney retransplantation.

Authors:  John S Thompson; Leroy R Thacker; Gopal Krishnan
Journal:  Transplantation       Date:  2003-03-15       Impact factor: 4.939

8.  Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease.

Authors:  Paul J Michaels; Maria L Espejo; Jon Kobashigawa; Juan C Alejos; Caron Burch; Steve Takemoto; Elaine F Reed; Michael C Fishbein
Journal:  J Heart Lung Transplant       Date:  2003-01       Impact factor: 10.247

9.  Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome.

Authors:  Judith E Worthington; Susan Martin; Dalia M Al-Husseini; Philip A Dyer; Robert W G Johnson
Journal:  Transplantation       Date:  2003-04-15       Impact factor: 4.939

10.  Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities.

Authors:  Rui Pei; Jar-How Lee; Neng-Jen Shih; Mike Chen; Paul I Terasaki
Journal:  Transplantation       Date:  2003-01-15       Impact factor: 4.939

View more
  15 in total

1.  Early acute antibody-mediated rejection of a negative flow crossmatch 3rd kidney transplant with exclusive disparity at HLA-DP.

Authors:  Beata Mierzejewska; Paul M Schroder; Caitlin E Baum; Annette Blair; Connie Smith; Rene J Duquesnoy; Marilyn Marrari; Amira Gohara; Deepak Malhotra; Dinkar Kaw; Robert Liwski; Michael A Rees; Stanislaw Stepkowski
Journal:  Hum Immunol       Date:  2014-04-19       Impact factor: 2.850

Review 2.  HLA epitope matching in pediatric renal transplantation.

Authors:  Matthew P Sypek; Peter Hughes; Joshua Y Kausman
Journal:  Pediatr Nephrol       Date:  2016-12-19       Impact factor: 3.714

3.  Why can sensitization by an HLA-DR2 mismatch lead to antibodies that react also with HLA-DR1?

Authors:  Marilyn Marrari; Rene J Duquesnoy
Journal:  Hum Immunol       Date:  2009-03-09       Impact factor: 2.850

Review 4.  Human Leukocyte Antigen Sensitization in Solid Organ Transplantation: A Primer on Terminology, Testing, and Clinical Significance for the Apheresis Practitioner.

Authors:  Sarah Abbes; Ara Metjian; Alice Gray; Tereza Martinu; Laurie Snyder; Dong-Feng Chen; Matthew Ellis; Gowthami M Arepally; Oluwatoyosi Onwuemene
Journal:  Ther Apher Dial       Date:  2017-09-07       Impact factor: 1.762

5.  Common and well-documented HLA alleles: 2012 update to the CWD catalogue.

Authors:  S J Mack; P Cano; J A Hollenbach; J He; C K Hurley; D Middleton; M E Moraes; S E Pereira; J H Kempenich; E F Reed; M Setterholm; A G Smith; M G Tilanus; M Torres; M D Varney; C E M Voorter; G F Fischer; K Fleischhauer; D Goodridge; W Klitz; A-M Little; M Maiers; S G E Marsh; C R Müller; H Noreen; E H Rozemuller; A Sanchez-Mazas; D Senitzer; E Trachtenberg; Marcelo Fernandez-Vina
Journal:  Tissue Antigens       Date:  2013-04

6.  cPRA Increases With DQA, DPA, and DPB Unacceptable Antigens in the Canadian cPRA Calculator.

Authors:  K J Tinckam; R Liwski; D Pochinco; M Mousseau; A Grattan; P Nickerson; P Campbell
Journal:  Am J Transplant       Date:  2015-06-16       Impact factor: 8.086

7.  HLA antibody testing: a tool to facilitate not to prevent organ transplantation.

Authors:  Frans H J Claas
Journal:  Int J Immunogenet       Date:  2008-08       Impact factor: 1.466

8.  Humoral alloimmunity in transplantation: relevance of HLA epitope antigenicity and immunogenicity.

Authors:  René J Duquesnoy
Journal:  Front Immunol       Date:  2011-11-08       Impact factor: 7.561

9.  C1Q Assay Results in Complement-Dependent Cytotoxicity Crossmatch Negative Renal Transplant Candidates with Donor-Specific Antibodies: High Specificity but Low Sensitivity When Predicting Flow Crossmatch.

Authors:  José M Arreola-Guerra; Natalia Castelán; Adrián de Santiago; Adriana Arvizu; Norma Gonzalez-Tableros; Mayra López; Isaac Salcedo; Mario Vilatobá; Julio Granados; Luis E Morales-Buenrostro; Josefina Alberú
Journal:  J Transplant       Date:  2016-09-04

Review 10.  Reflections on HLA Epitope-Based Matching for Transplantation.

Authors:  Rene J Duquesnoy
Journal:  Front Immunol       Date:  2016-11-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.